---
title: 'Regional Medical Director, Gene Therapy at Genetix Biotherapeutics'
canonical: 'https://feeny.ai/job/regional-medical-director-gene-therapy-genetix-biotherapeutics-remote-wz9vc7s3xy0n'
type: 'job'
last_seen: '2026-09-07'
---

# Regional Medical Director, Gene Therapy at Genetix Biotherapeutics

- **Company:** Genetix Biotherapeutics
- **Location:** Remote
- **Compensation:** $225k–$275k
- **Work type:** remote
- **Posted:** 2026-08-17
- **Last confirmed live:** 2026-09-07
- **Apply:** https://job-boards.greenhouse.io/genetixbiotherapeutics/jobs/8132233

## Job description

## About Genetix Biotherapeutics

At Genetix Biotherapeutics every role has meaning, every team member is respected, and every day is a chance to make a difference. When you join Genetix, you're not just landing a new role, you become part of a company that's pursuing curative gene therapies to give patients and their families more days. We are doers, thinkers and collaborators who embrace and live by our values:

Our innovation is rooted in the diversity of our teams and results are achieved through cooperation and the integration of multiple viewpoints. This is personal and we approach every challenge with radical care.

This is a full-time, field-based opportunity with a preference for candidates located in the Southeast or Northeast regions of the United States.

The Medical Affairs group is driven by our responsibility to patients, our engaging science, and our opportunity to help the scientific community understand what Genetix is working on. Medical Affairs team serves as a trusted and reliable source of information about Genetix’s science to healthcare providers around the world. Through scientific and medical communications, we link the innovative science from our labs and clinical research to the patients in the clinic.

As the only company with three FDA approved gene therapy products, we have accomplished a lot and now we are driven to bring these therapies to a growing number of deserving patients. They have waited a long time for the cutting-edge science to be brought to the clinic, a goal now accomplished by amazing Genetix team. We move with a sense of urgency that reflects our commitment to people suffering from severe genetic diseases and we remember to support each other and have fun doing it!

## RESPONSIBILITIES

As a member of the Medical Affairs Leadership Team, the Regional Medical Director (RMD) of Gene Thereapy will serve as a subject matter expert and team leader for programs/indications supporting our gene therapy portfolio. The RMD will be an integral member of Medical Affairs and will lead efforts to bridge clinical science and and commercial efforts by ensuring strategic alignment across various internal and external functions and help shape our global gene therapy strategy. On a day-to-day basis, the RMD will focus on peer-to-peer interactions, the development and execution of advisory boards, KOL advocacy, congress presence, and medical symposia. Additionally, the RMD will provide structured feedback to internal teams relative to actionable field insights, help to advance data generation efforts, and ensure team members deliver measurable impact on clinical understanding, access, and appropriate use.

- Develop and execute Medical Affairs strategy: This includes contributing to the comprehensive strategy for gene therapy across sickle cell disease (SCD) and transfusion dependent thalassemia (TDT) ensuring alignment with the overall company strategy and development of medical plans with supporting the company’s goals and milestones.
- Build external relationships: Develop external relationships to provide scientific and clinical information on our therapies to key HCP and bring actionable insights from the KOL and treating physicians. Scientific exchange is a key element of this role.
- Cultivate KOL Advocacy: Engage with trusted, highly influential industry experts to garner support for Genetix’s scientific message, clinical research, and product value with the goal of developing a strategic partnership that enhances product credibility and helps to influence clinical practices.
- Provide medical leadership to Genetix’s cross-functional teams: Offer medical expertise and input to other teams including commercial, clinical, operations, payor, and advocacy, in support of enhance patient outcomes. Facilitate a strong and consistent medical voice by driving company-wide adoption of the scientific platform and lexicon. Work strategically to break down silos, build trusting relationships, and maximize the utilization data-driven science to manage complex healthcare challenges.
- Contribute to medical education and communications: Support the creation of evidence-based content that enhances patient-provider communication. Provide feedback to internal stakeholders that aides in the development of tools to improve health literacy and foster empathy.
- Researching and exploring scientific presentations and publications: Collect the latest data from publications and presentations, gather competitive intelligence in the relevant areas of activity, and summarize key findings for the internal team. Maintain proficiency in the effective delivery of scientific information via in-person, virtual, and hybrid formats utilizing visual aids with a clear narrative that emphasizes results.
- Ensure compliance: Maintain compliance with applicable company policies and regulations. Ensure that activities including the management, generation, and dissemination of clinical and non-clinical data are conducted with integrity and scientific accuracy.

## QUALIFICATIONS

- Medical degree (MD or equivalent) degree, or advanced scientific or clinical training (for example, Ph.D., PharmD or MSN) with at least 7 years of previous combined experience in relevant patient care and/or Medical Affairs.
- Ability to build and maintain relationships with key opinion leaders and other external stakeholders.
- Previous experience in Hematopoietic Stem Cell Transplantation, Cell and Gene Therapy or other biologic therapies is required; experience with hemoglobinopathies such as TDT and SCD are also valued. It is important to have strong scientific expertise and the ability to explain complex concepts clearly.
- Residence in the Southeast or Northeast US preferred. Must have the ability to travel frequently to the treatment centers, referring practices, academic conferences and other engagements.
- Excellent communication, presentation, and interpersonal skills. Ability to lead technical and business discussions internally and externally.

Additional Information

The pay transparency range provided below is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. We may ultimately pay more or less than the posted range, and the range may be modified in the future. This role is eligible for an annual bonus and long-term incentive. Actual base salary pay will be based on several factors, including but not limited to experience, skills, relevant education/qualifications, external market, internal equity, and other job-related factors permitted by law.

Genetix’s total rewards package also provides employees with a comprehensive and competitive benefits suite to support a variety of employee needs. These benefits include comprehensive health, life and disability insurance, employer-matched 401(k) plan, lifestyle spending account, flexible time-off + paid holidays and winter holiday period, tuition reimbursement & loan repayment assistance, paid parental leave, paid onsite parking, commuter subsidy, and much more.

Pay Transparency $225,000—$275,000 USD

Genetix is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, veteran status or any other applicable legally protected characteristics.

## About Genetix Biotherapeutics

## Company Overview
- **One-liner**: Genetix Biotherapeutics (formerly bluebird bio) is a commercial-stage biotechnology company dedicated to developing and delivering one-time, curative genetic therapies for patients with severe rare genetic diseases.
- **Entity Type**: Private (taken private in June 2025 after a sale to new ownership)
- **Headquarters**: Somerville, Massachusetts, USA (with a presence in the Netherlands)
- **Founded**: 1992 (founded as Genetix Pharmaceuticals; rebranded to bluebird bio in 2010; rebranded back to Genetix Biotherapeutics in September 2025)
- **Founders**: Not publicly disclosed; the company was originally founded as Genetix Pharmaceuticals in 1992.

## Core Business
- **Primary Industries**: Biotechnology, Gene Therapy, Rare Disease Therapeutics
- **Target Customers**: B2B (healthcare providers, qualified treatment centers, payers/insurers) and B2C (patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy)
- **Mission**: "To transform lives through curative therapies for patients with rare, genetic diseases."

## Products & Services
- **LYFGENIA™ (lovotibeglogene autotemcel / lovo-cel)**: An FDA-approved, one-time gene therapy for patients 12 years and older with sickle cell disease. It works by adding functional copies of a modified β-globin gene into the patient's own blood stem cells.
- **ZYNTEGLO™ (betibeglogene autotemcel)**: An FDA-approved, one-time gene therapy for patients with β-thalassemia who require regular blood transfusions. It adds functional copies of a modified β-globin gene into the patient's own blood stem cells.
- **SKYSONA™ (elivaldogene autotemcel)**: An FDA-approved, one-time gene therapy for boys with cerebral adrenoleukodystrophy (CALD), a rare, progressive genetic brain disease. It adds a functional copy of the ABCD1 gene into the patient's own blood stem cells.
- **Patient Support Program**: Personalized assistance for patients and families navigating the treatment journey, including insurance questions, treatment center coordination, and one-on-one support.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (privately held after take-private transaction in June 2025)
- **Key Metrics**:
  - **Annual Revenue**: Not publicly disclosed (but the company reported strong revenue growth in 2025 and achieved its **first ever profitable quarter** in that year)
  - **Total Funding**: Not publicly disclosed (new investors provided "significant capital" to support operational objectives following the take-private transaction)
- **Notable Investors/Partners**: New ownership group (undisclosed); manufacturing partners include **Minaris**, **Lonza**, and **MilliporeSigma** (the U.S. and Canada business of Merck KGaA, Darmstadt, Germany)
- **Growth Signals**:
  - **2025 commercial performance**: >100 patients treated in the U.S.; >150 patients completed their first cell collection cycle; 70 active Qualified Treatment Centers (QTCs) — the largest network for hemoglobinopathy gene therapies nationwide
  - **2026 outlook**: Doubling manufacturing capacity by mid-2026; targeting first full year of profitability; expanding LYFGENIA label to pediatric patients <12 years of age; advancing cryopreserved apheresis to improve the treatment experience

## Competitive Advantages
- **First-mover & market leader**: The only company with FDA approval for three gene therapies, and the market leader in the U.S. for hemoglobinopathy gene therapies
- **Proven commercial model**: >100 patients treated in a single year demonstrates real-world commercial execution and manufacturing scale
- **Decades of scientific innovation**: Over 30 years of R&D in genetic therapy, with extensive clinical data from hundreds of treated patients (including 15-year long-term follow-up studies)
- **Strong access**: LYFGENIA and ZYNTEGLO have meaningful access for >90% of eligible patients with commercial or Medicaid coverage
- **One-time curative approach**: Therapies are designed to treat the underlying cause of disease, offering durable, potentially life-long benefits from a single administration

## Strategic Focus
- **Commercial execution & patient access**: Expanding the Qualified Treatment Center network and making the treatment journey simpler for patients and providers
- **Manufacturing scale-up**: Doubling manufacturing capacity in 2026 through partnerships with CDMOs to meet growing patient demand
- **Process optimization**: Implementing cryopreserved apheresis to improve the patient and provider experience
- **Label expansion**: Advancing the HGB-210 Phase 3 study to bring LYFGENIA to pediatric sickle cell patients under 12 years of age
- **Full-year profitability**: Targeting the company's first full year of profitability in 2026

## Why Work Here
- **Mission-driven culture**: "United by purpose" — the company is laser-focused on transforming the lives of patients with rare, genetic diseases through curative therapies
- **Strong momentum**: Recently achieved first-ever profitable quarter, with rapid commercial growth and a clear plan for expansion in 2026
- **Remote/hybrid policy**: Roles are listed as both on-site (Somerville, MA) and remote (e.g., Account Manager, Gene Therapy) — flexible arrangements appear available depending on the role
- **Active hiring**: 23 job postings as of the search date, spanning Commercial, Quality Assurance, Technical Operations, Medical, and Regulatory functions
- **Experienced leadership**: Led by CEO David Meek (ex-Mirati Therapeutics, Ipsen) with a seasoned executive team of industry veterans, signaling strong strategic direction
- **Notable perks/culture**: High-impact work at the intersection of cutting-edge science and commercial execution; opportunity to join a company in the middle of a dramatic turnaround and growth phase; patient-centric focus with a dedicated support program

## Sources
1. [genetixbiotx.com - Company website](https://www.genetixbiotx.com/)
2. [job-boards.greenhouse.io - Careers page](http://job-boards.greenhouse.io/genetixbiotherapeutics)
3. [linkedin.com - LinkedIn company page](https://www.linkedin.com/company/genetix-biotherapeutics)
4. [genetixbiotx.com - Press release: Rebrand from bluebird bio](https://www.genetixbiotx.com/press-release-2025-09-18.html)
5. [genetixbiotx.com - Press release: 2025 commercial results & 2026 priorities](https://www.genetixbiotx.com/press-release-2026-03-02.html)

## Other roles at Genetix Biotherapeutics

- [Sr. Manager - IT Commercial and Medical Systems](https://feeny.ai/job/sr-manager-it-commercial-and-medical-systems-genetix-biotherapeutics-somerville-drs30kf4perv) — Somerville, MA
- [Sr. Director, Regulatory Strategy](https://feeny.ai/job/sr-director-regulatory-strategy-genetix-biotherapeutics-somerville-fpj4qjceza7s) — Somerville, MA
- [Manager, End User Services & Lab Support](https://feeny.ai/job/manager-end-user-services-lab-support-genetix-biotherapeutics-somerville-q2ah951d4k1c) — Somerville, MA
- [Director, Regulatory Advertising and Promotion](https://feeny.ai/job/director-regulatory-advertising-and-promotion-genetix-biotherapeutics-somerville-4ykm3383hgsq) — Somerville, MA
- [Paralegal and Legal & Compliance Operations Manager](https://feeny.ai/job/paralegal-and-legal-compliance-operations-manager-genetix-biotherapeutics-m768zfn33tct) — Somerville, MA
- [Associate Manager, Quality Assurance Operations](https://feeny.ai/job/associate-manager-quality-assurance-operations-genetix-biotherapeutics-8m008cez8h16) — Somerville, MA
- [Sr. Manager, Quality Assurance for Quality Control](https://feeny.ai/job/sr-manager-quality-assurance-for-quality-control-genetix-biotherapeutics-j6a4xrp93mf0) — Somerville, MA
- [Director, Value Communications](https://feeny.ai/job/director-value-communications-genetix-biotherapeutics-somerville-yxp6wwwsrt3f) — Somerville, MA
- [Account Manager, Gene Therapy - Pacific Northwest](https://feeny.ai/job/account-manager-gene-therapy-pacific-northwest-genetix-biotherapeutics-seattle-cdgars1xqtra) — Seattle, WA
- [Director of Scientific Communications & Evidence Generation](https://feeny.ai/job/director-of-scientific-communications-evidence-generation-genetix-ddek20fjzkgt) — Somerville, MA